Cointime

SIGA Technologies

company

About

At SIGA, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox.

  • 1 - 10

Highlights

Total Funding Amount
$58M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$3M
Industries
Biotechnology
Founded date
Jan 1, 1995
Number Of Employee
1 - 10
Operating Status
Active

SIGA is a pharmaceutical company specializing in the development of pharmaceutical solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$58M
SIGA Technologies has raised a total of $58M in funding over 2 rounds. Their latest funding was raised on Sep 2, 2009 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 2, 2009 Grant $3M 1 National Institutes of Health — Detail
Sep 3, 2008 Grant $55M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
SIGA Technologies is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Cointime
Содержание
компания